zum Inhalt springen


As a research partner the CTCC assists a clincal trial from the beginning up to publication. The following publication list provides a selection of the scientific cooperations with CTCC experts involved.


Oliver A. Cornely 1†, Jose´ M. Cisneros2*†, Julian Torre-Cisneros3, Marı´a Jesu´s Rodrı´guez-Herna´ndez2,
Luis Tallo´n-Aguilar4, Esther Calbo5, Juan P. Horcajada6, Christian Queckenberg1, Ulrike Zettelmeyer1,
Dorothee Arenz1, Clara M. Rosso-Ferna´ndez2, Silvia Jime´nez-Jorge2, Guy Turner7, Susan Raber8, Seamus O’Brien7
and Alison Luckey7 on behalf of the COMBACTE-CARE consortium/REJUVENATE Study Group  Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study J Antimicrob Chemother 2020; 75: 618–627 doi:10.1093/jac/dkz497 Advance Access publication 12 December 2019

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M,et.al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14

Grzella AN, Schleicher S, Shah-Hosseini K, Astvatsatourov A, Raskopf E, Allekotte S, Mösges R, Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing. Int Arch Allergy Immunol. 2019; Mar 25:1-9. (doi: 10.1159/000496938)


Köther J, Mandl A, Allekotte S, Astvatsatourov A, Chwieralski J, Liedtke JP, Pieper-Fürst U, Raskopf E, Shah-Hosseini K, Mösges R. Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy. Clin Transl Allergy. 2018 Jul 4; 8:28.

Pfaar O, Claßen DP, Astvatsatourov A, Klimek L, Mösges R. Reliability of a New Symptom Score in a Titrated Quantitative Conjunctival Provocation Test Supported by an Objective Photodocumentation. Int Arch Allergy Immunol 2018; 176(3-4):215-224.

Schaub F, Hoerster R, Schiller P, Felsch M, Kraus D, Zarrouk M, Kirchhof B, Fauser S Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial. Trials. 2018 Jul 16;19(1):384. doi: 10.1186/s13063-018-2761-x.


Brosteanu, O, Schwarz, G, Houben, P, Paulus, U, Strenge-Hesse, A, Zettelmeyer, U, Schneider, A, Hasenclever, D: Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study. Clinical Trials. 2017;8 (1-13)  

Wilcox, MH, Gerding, DN, Poxton, IR, Kelly, C, , Nathan, R, Birch, T, Cornely, OA, Rahav, G, Bouza, E, Lee, C, Jenkin, G, Jensen, W, Kim, Y-S, Yoshida, J, Gabryelski, L, Pedley, A, Eves, K, Tipping, R, Guris, D, Kartsonis, N, Dorr, M-B for the MODIFY I and MODIFY II Investigators. N Engl J Med 2017; 376:305-317. 2017 January 26

Koy, A, Kühn, A, van Riesen, A, Huebl, J, Korinthenberg, R, Coenen, VA, Krauss, JK, Wloch, A, Lorenz, D, Häussler, M, Schnitzler, A, Vesper, J, Alesch, F, Lehmacher, W, Mueller, J, Borck, G, Witt, K, Bäumer, T, Berweck, S, Schröder, S, Voges, J, Prinz-Langenohl, R, Visser-Vandewalle, V, , Hellmich, M, Timmermann, L and STIM-CP investigators: Effect of Deep Brain Stimulation of the Globus Pallidus Internus on Quality of Life in Young Patients with Dyskinetic Cerebral Palsy (STIM-CP): a Prospective Single-Arm Multicenter Trial with a Double-Blind Cross-Over at 12-Months Follow-up. J Clin Trials 7:1000317. doi: 10.4172/2167-0870.1000317


Michalik C, Skaletz-Rorowski A, Brockmeyer NH: The Competence Network for HIV/AIDS. Data, Samples, Facts. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016;59(4): 489-96

Simon ST, Kloke M, Alt-Epping B, Gärtner J, Hellmich M, Hein R, Piel M, Cornely OA, Nauck F, Voltz R: EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. J Pain Symptom Manage. 2016;52(5): 617-625

Barbe MT, Franklin J, Kraus D, Reker P, Dembek TA, Allert N, Wirths J, Voges J, Timmermann L, Visser-Vandewalle V: Deep brain stimulation of the posterior subthalamic area and the thalamus in patients with essential tremor: study protocol for a randomized controlled pilot trial. Trials. 2016;17(1): 476  


S Liakopoulos OJ, Kuhn EW, Hellmich M, Kuhr K, Krause P, Reuter H, Thurat M, Choi YH, Wahlers T: Statin Recapture Therapy before Coronary Artery Bypass Grafting Trial: Rationale and study design of a multicenter, randomized, double-blinded controlled clinical trial. Am Heart J. 2015;170(1): 46-54, 54.e1-2

Queckenberg C, Erlinghagen V, Baken BC, Van Os SH, Wargenau M, Kube? V, Peroutka R, Novotný V, Fuhr U : Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations. Cancer Chemother Pharmacol. 2015;76(5): 1081-91

Kohlmann R, Salmen A, Chan A, Knabbe C, Diekmann J, Brockmeyer N, Skaletz-Rorowski A, Michalik C, Gold R, Überla K: Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis. Mult Scler. 2015;21(14): 1823-32

Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557): 487-91

Kaasch AJ, Fätkenheuer G, Prinz-Langenohl R, Paulus U, Hellmich M, Weiß V, Jung N, Rieg S, Kern WV, Seifert H, SABATO trial group (with linked authorship to the individuals in the Acknowledgements section) , Fätkenheuer G, Jung N, Kaasch AJ, Seifert H, Hellmich M, Weiß V, Lewalter K, Lemmen S, Stijnis C, van der Meer J, Soriano A, Ruiz LM, Arastéh K, Stocker H, Kluytmans J, Veenemans J, Brodt HR, Stephan C, Wolf T, Kessel J, Kern WV, Rieg S, Joost I, Sinha B, van Assen S, Wilting K, Welte T, Mölgen C, Brunkhorst JF, Pletz M, Hagel S, Becker C, Frieling T, Kösters K, Reuter S, Hsiao M, Rupp J, Dalhoff K, Turner D, Snape S, Crusz S, Venkatesan P, Salzberger B, Hanses F, Rodriguez-Baño J, Méndez AV, Cortés LE, Cisneros JM, Navarro-Amuedo MD, Bonten M, Oosterheert JJ, Ekkelenkamp M: Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial. Trials. 2015;16: 450

Preceding years

1. Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin. Microbiol. Infect. 2014; 20 Suppl 3:76–98.

2. Arenz D, Hero B, Eichhorst BF, Langer M, Pester L, Tresckow J von, Vehreschild JJ, Vehreschild MJ, Cornely OA. Estimating site costs prior to conducting clinical trials. Clinical Investigation 2014; 4(3):227–34.

3. Bacher P, Kniemeyer O, Schönbrunn A, Sawitzki B, Assenmacher M, Rietschel E, Steinbach A, Cornely OA, Brakhage AA, Thiel A, Scheffold A. Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi. Mucosal Immunol 2014; 7(4):916–28.

4. Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJGT. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective. Crit. Rev. Microbiol. 2014.

5. Buchheidt D, Spiess B, Cornely OA, Vehreschild MJGT, Hamprecht A, Rath P, Steinmann J, Groß U, Bader O, Lauten M, Reinwald M, Hofmann W. Azol-Resistenz bei Aspergillus fumigatus - Epidemiologie und Nachweis bei immunsupprimierten Patienten in Deutschland. Dtsch. Med. Wochenschr. 2014; 139(25-26):1373–6.

6. Chowdhary A, Meis JF, Guarro J, Hoog GS de, Kathuria S, Arendrup MC, Arikan-Akdagli S, Akova M, Boekhout T, Caira M, Guinea J, Chakrabarti A, Dannaoui E, van Diepeningen A, Freiberger T, Groll AH, Hope WW, Johnson E, Lackner M, Lagrou K, Lanternier F, Lass-Flörl C, Lortholary O, Meletiadis J, Muñoz P, Pagano L, Petrikkos G, Richardson MD, Roilides E, Skiada A, Tortorano AM, Ullmann AJ, Verweij PE, Cornely OA, Cuenca-Estrella M. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin. Microbiol. Infect. 2014; 20 Suppl 3:47–75.

7. Cornely OA. Invasive Pilzinfektionen: Aspergillose, Candidose, Mucormykose. Drug Res (Stuttg) 2014; 64 Suppl 1:S14-5.

8. Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Freiberger T, Guinea J, Guarro J, Hoog S de, Hope W, Johnson E, Kathuria S, Lackner M, Lass-Flörl C, Lortholary O, Meis JF, Meletiadis J, Muñoz P, Richardson M, Roilides E, Tortorano AM, Ullmann AJ, van Diepeningen A, Verweij P, Petrikkos G. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin. Microbiol. Infect. 2014; 20 Suppl 3:5–26.

9. Cornely OA, Cuenca-Estrella M, Meis JF, Ullmann AJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clin. Microbiol. Infect. 2014; 20 Suppl 3:1–4.

10. Cornely OA. Editorial commentary: galactomannan testing during mold-active prophylaxis. Clin. Infect. Dis. 2014; 59(12):1703–4.

11. Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IAO. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J. Antimicrob. Chemother. 2014; 69(11):2892–900.

12. Cornely OA, Vazquez J, Waele J de, Betts R, Rotstein C, Nucci M, Pappas PG, Ullmann AJ. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species. Mycoses 2014; 57(2):79–89.

13. Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J. Antimicrob. Chemother. 2014.

14. Duarte RF, López-Jiménez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, Chandrasekar P, Langston A, Perfect J, Ma L, van Iersel MLPS, Connelly N, Kartsonis N, Waskin H. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob. Agents Chemother. 2014; 58(10):5758–65.

15. Ehren K, Hertenstein C, Kümmerle T, Vehreschild JJ, Fischer J, Gillor D, Wyen C, Lehmann C, Cornely OA, Jung N, Gravemann S, Platten M, Wasmuth JC, Rockstroh JK, Boesecke C, Schwarze-Zander C, Fätkenheuer G. Causes of death in HIV-infected patients from the Cologne-Bonn cohort. Infection 2014; 42(1):135–40.

16. Heimann SM, Cornely OA, Wisplinghoff H, Kochanek M, Stippel D, Padosch SA, Langebartels G, Reuter H, Reiner M, Vierzig A, Seifert H, Vehreschild MJGT, Glossmann J, Franke B, Vehreschild JJ. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 2014.

17. Heimann SM, Vehreschild MJGT, Cornely OA, Franke B, Bergwelt-Baildon M von, Wisplinghoff H, Kron F, Scheid C, Vehreschild JJ. A Cost and Resource Utilization Analysis of Micafungin-Bridging for Hemato-Oncological High-Risk Patients Undergoing Allogeneic Stem Cell Transplantation. Eur. J. Haematol. 2014.

18. Heimann SM, Vehreschild MJGT, Meintker L, Heinz W, Schroeder T, Bergwelt-Baildon M von, Cornely OA, Vehreschild JJ. Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany. Transpl Infect Dis 2014.

19. Heimann SM, Cornely OA, Vehreschild MJGT, Glossmann J, Kochanek M, Kreuzer K, Hallek M, Vehreschild JJ. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis. Mycoses 2014; 57(2):90–7.

20. Hünseler C, Balling G, Röhlig C, Blickheuser R, Trieschmann U, Lieser U, Dohna-Schwake C, Gebauer C, Möller O, Hering F, Hoehn T, Schubert S, Hentschel R, Huth RG, Müller A, Müller C, Wassmer G, Hahn M, Harnischmacher U, Behr J, Roth B. Continuous infusion of clonidine in ventilated newborns and infants: a randomized controlled trial. Pediatr Crit Care Med 2014; 15(6):511–22.

21. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin. Infect. Dis. 2014; 59(3):345–54.

22. Koehler P, Tacke D, Cornely OA. Aspergillosis of bones and joints - a review from 2002 until today. Mycoses 2014; 57(6):323–35.

23. Koehler P, Tacke D, Cornely OA. Bone and joint infections by Mucorales, Scedosporium, Fusarium and even rarer fungi. Crit. Rev. Microbiol. 2014:1–14.

24. Koehler P, Tacke D, Cornely OA. Our 2014 approach to candidaemia. Mycoses 2014; 57(10):581–3.

25. Lenk C, Duttge G, Fangerau H. Handbuch Ethik und Recht der Forschung am Menschen. Berlin Heidelberg: Springer Berlin Heidelberg; 2014.

26. Maertens J, Cornely OA, Ullmann AJ, Heinz WJ, Krishna G, Patino H, Caceres M, Kartsonis N, Waskin H, Robertson MN. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob. Agents Chemother. 2014; 58(7):3610–7.

27. Michalik C, Dress J, Ngouongo S, Stäubert S, Weber U, Brockmeyer N, Paulus U, Stausberg J. Requirements and tasks of cohorts and registers, the German KoRegIT project. Stud Health Technol Inform 2014; 205:1085–9.

28. Moenkemann H, Pilger R, Reinecker S, Houben P, Paulus U. Comprehensive and effective system of standard operating procedures for investigator-initiated trials. Clinical Investigation 2014; 4(2):115–23.

29. Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G, Krüger W, Link H, Neumann S, Ostermann H, Panse J, Penack O, Rieger C, Schmidt-Hieber M, Silling G, Südhoff T, Ullmann AJ, Wolf H, Maschmeyer G, Böhme A. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol. 2014; 93(1):13–32.

30. Nathwani D, Cornely OA, van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IAO. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J. Antimicrob. Chemother. 2014; 69(11):2901–12.

31. Nucci M, Marr KA, Vehreschild MJGT, Souza CA de, Velasco E, Cappellano P, Carlesse F, Queiroz-Telles F, Sheppard DC, Kindo A, Cesaro S, Hamerschlak N, Solza C, Heinz WJ, Schaller M, Atalla A, Arikan-Akdagli S, Bertz H, Galvão Castro C, Herbrecht R, Hoenigl M, Härter G, Hermansen NEU, Josting A, Pagano L, Salles MJC, Mossad SB, Ogunc D, Pasqualotto AC, Araujo V, Troke PF, Lortholary O, Cornely OA, Anaissie E. Improvement in the outcome of invasive fusariosis in the last decade. Clin. Microbiol. Infect. 2014; 20(6):580–5.

32. Platten M, Linnemann R, Kümmerle T, Jung N, Wyen C, Ehren K, Gravemann S, Gillor D, Cornely OA, Fischer J, Lehmann C, Rockstroh JK, Fätkenheuer G, Vehreschild JJ. Clinical course and quality of care in ART-naïve patients newly presenting in a HIV outpatient clinic. Infection 2014; 42(5):849–57.

33. Schweer KE, Wittersheim M, Bangard C, Frank KF, Cornely OA. Chronische pulmonale Aspergillose. Vier klinische Fallbeispiele und Überblick über die aktuelle Literatur. Dtsch. Med. Wochenschr. 2014; 139(44):2242–7.

34. Simon ST, Kloke M, Voltz R, Nauck F, Piel M, Hellmich M, Vangierdegom C, Alt-Epping B. Barrieren und Strategien bei der Konzeption und Durchführung einer klinischen Studie in der Palliativmedizin am Beispiel der IIT EffenDys. Palliativmedizin 2014; 15(03).

35. Spiess B, Postina P, Reinwald M, Cornely OA, Hamprecht A, Hoenigl M, Lass-Flörl C, Rath P, Steinmann J, Miethke T, Lauten M, Will S, Merker N, Hofmann W, Buchheidt D. Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013. PLoS ONE 2014; 9(7):e103113.

36. Tacke D, Buchheidt D, Karthaus M, Krause SW, Maschmeyer G, Neumann S, Ostermann H, Penack O, Rieger C, Ruhnke M, Sandherr M, Schweer KE, Ullmann AJ, Cornely OA. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Ann. Hematol. 2014; 93(9):1449–56.

37. Tacke D, Koehler P, Markiefka B, Cornely OA. Our 2014 approach to mucormycosis. Mycoses 2014; 57(9):519–24.

38. Tortorano AM, Richardson M, Roilides E, van Diepeningen A, Caira M, Munoz P, Johnson E, Meletiadis J, Pana Z, Lackner M, Verweij P, Freiberger T, Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Guinea J, Guarro J, Hoog S de, Hope W, Kathuria S, Lortholary O, Meis JF, Ullmann AJ, Petrikkos G, Lass-Flörl C. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin. Microbiol. Infect. 2014; 20 Suppl 3:27–46.

39. Vehreschild JJ, Böhme A, Cornely OA, Kahl C, Karthaus M, Kreuzer K, Maschmeyer G, Mousset S, Ossendorf V, Penack O, Vehreschild MJGT, Bohlius J. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Ann. Oncol. 2014; 25(9):1709–18.

40. Vehreschild JJ, Vehreschild MJGT, Cornely OA. PTX3 deficiency and aspergillosis. N. Engl. J. Med. 2014; 370(17):1666.

41. Vehreschild MJGT, Bergwelt-Baildon M von, Tran L, Shimabukuro-Vornhagen A, Wisplinghoff H, Bangard C, Cornely OA, Vehreschild JJ. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients. Eur. J. Haematol. 2014; 93(5):400–6.

42. Vehreschild MJGT, Hamprecht A, Peterson L, Schubert S, Häntschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal MV, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild JJ, Cornely OA, Seifert H. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J. Antimicrob. Chemother. 2014; 69(12):3387–92.

43. Vehreschild MJGT, Weitershagen D, Biehl LM, Tacke D, Waldschmidt D, Töx U, Wisplinghoff H, Bergwelt-Baildon MV, Cornely OA, Vehreschild JJ. Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis. Biol. Blood Marrow Transplant. 2014; 20(6):823–8.

44. Wille S, Tenholte D, Cornely O, Muthen N, Engelmann U, Mehner J, Eminaga O, Herden J, Schumacher P, Paas J. Prädiktion der Therapie der überaktiven Blase mittels katheterloser Langzeiturodynamik. Urologe 2014.

45. Wille S, Schumacher P, Paas J, Tenholte D, Eminaga O, Müller U, Muthen N, Mehner J, Cornely O, Engelmann U, Barbosa MA. Catheterless Long-Term Ambulatory Urodynamic Measurement Using a Novel Three-Device System. PLoS ONE 2014; 9(5):e96280.

46. Comment of an Expert Group of the Paul-Ehrlich-Society for Chemotherapy on the benefit assessment of fidaxomicin for treatment of Clostridium difficile infections. GMS Infectious Diseases 2013 Nov 19.

47. Cornely OA, Miller MA, Fantin BR, Mullane KM, Kean Y, Gorbach SL. Reply to M.R. Green et al. J. Clin. Oncol. 2013; 31(34):4379.

48. Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J. Clin. Oncol. 2013; 31(19):2493–9.

49. Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, Luca A de, Jansen K, Wit S de, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A, Lodwick R, Günthard HF, Michalik C, Chrysos G. Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. J. Infect. Dis. 2013; 207(5):759–67.

50. Farowski F, Cornely OA, Vehreschild JJ, Wiesen M, Steinbach A, Vehreschild MJGT, Müller C. Intracellular concentrations of anidulafungin in different compartments of the peripheral blood. Int. J. Antimicrob. Agents 2013; 41(4):379–82.

51. Glöckner A, Cornely OA. Invasive Candida-Infektionen bei nichtneutropenischen Erwachsenen: Leitlinienbasiertes Management auf der Intensivstation. Anaesthesist 2013; 62(12):1003–9.

52. Glöckner A, Cornely OA. Practical considerations on current guidelines for the management of non-neutropenic adult patients with candidaemia. Mycoses 2013; 56(1):11–20.

53. Grählert X, Bruns I, Paulus U. ,Zweites Änderungsgesetz': Konsequenzen für die akademische klinische Forschung. Pharmazeutische Medizin 2013; 15(2):68–73.

54. Jansen K, Haastert B, Michalik C, Guignard A, Esser S, Dupke S, Plettenberg A, Skaletz-Rorowski A, Brockmeyer NH. Incidence and risk factors of herpes zoster among hiv-positive patients in the german competence network for HIV/AIDS (KompNet): a cohort study analysis. BMC Infect Dis 2013; 13(1):372.

55. Knöll P, Oppermann J, Vehreschild J, Beyer F, Kaulhausen T, Siewe J, Stein G, Otto C, Cornely O, Eysel P, Wyen H, Jakob V, Neugebauer E, Zarghooni K. Als Kliniker Rotand im CHIR-Net: Evaluation des Kurrikulums. Chirurg 2013.

56. Knöll P, Oppermann J, Vehreschild J, Beyer F, Kaulhausen T, Siewe J, Stein G, Otto C, Cornely O, Eysel P, Wyen H, Jakob V, Neugebauer E, Zarghooni K. Als Kliniker Rotand im CHIR-Net. Evaluation des Kurrikulums. Chirurg 2013; 84(12):1062–6.

57. Maschmeyer G, Heinz WJ, Hertenstein B, Horst H, Requadt C, Wagner T, Cornely OA, Löffler J, Ruhnke M. Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study. Eur. J. Clin. Microbiol. Infect. Dis. 2013; 32(5):679–89.

58. Mönkemann H, Pilger R, Reinecker S, Houben P, Paulus U. Comprehensive and Effective System of Standard Operating Procedures for Investigator Initiated Trials. Clinical Investigation 2013.

59. Mullane KM, Cornely OA, Crook DW, Golan Y, Louie TJ, Miller MA, Josephson MA, Gorbach SL. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am. J. Nephrol. 2013; 38(1):1–11.

60. Pagano L, Cornely OA, Busca A, Caira M, Cesaro S, Gasbarrino C, Girmenia C, Heinz WJ, Herbrecht R, Lass-Flörl C, Nosari A, Potenza L, Racil Z, Rickerts V, Sheppard DC, Simon A, Ullmann AJ, Valentini CG, Vehreschild JJ, Candoni A, Vehreschild MJGT. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica 2013; 98(10):e127-30.

61. Reinwald M, Spiess B, Heinz WJ, Heussel CP, Bertz H, Cornely OA, Hahn J, Lehrnbecher T, Kiehl M, Laws HJ, Wolf HH, Schwerdtfeger R, Schultheis B, Burchardt A, Klein M, Dürken M, Claus B, Schlegel F, Hummel M, Hofmann W, Buchheidt D. Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive Aspergillosis enhances diagnostic capabilities. J. Clin. Microbiol. 2013; 51(12):4178–85.

62. Svedhem-Johansson V, Pugliese P, Brockmeyer NH, Thalme A, Michalik C, Esser S, Barlet M, Nakonz T, Jimenez-Exposito MJ. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr. HIV Res. 2013; 11(4):333–41.

63. Tacke D, Koehler P, Cornely OA. Fungal endocarditis. Curr. Opin. Infect. Dis. 2013; 26(6):501–7.

64. Tenholte D, Wille S, Hamacher J, Muthen N, Schumacher P, Engelmann U, Mehner J. An Intravesical Measurement System for Catheterless Long-Term Urodynamics. Biomed Tech (Berl) 2013.

65. Vehreschild JJ, Morgen G, Cornely OA, Hartmann P, Koch S, Kalka-Moll W, Wyen C, Vehreschild MJGT, Lehmann C, Gillor D, Seifert H, Kremer G, Fätkenheuer G, Jung N. Evaluation of an infectious disease consultation programme in a German tertiary care hospital. Infection 2013; 41(6):1121–8.

66. Vehreschild JJ, Birtel A, Vehreschild MJGT, Liss B, Farowski F, Kochanek M, Sieniawski M, Steinbach A, Wahlers K, Fätkenheuer G, Cornely OA. Mucormycosis treated with posaconazole: review of 96 case reports. Crit. Rev. Microbiol. 2013; 39(3):310–24.

67. Vehreschild MJGT, Liss BJ, Cornely OA. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 2013; 41(5):1049–50.

68. Vehreschild MJGT, Vehreschild JJ, Hübel K, Hentrich M, Schmidt-Hieber M, Christopeit M, Maschmeyer G, Schalk E, Cornely OA, Neumann S. Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Oncol. 2013; 24(5):1189–202.

69. Welzing L, Link F, Junghaenel S, Oberthuer A, Harnischmacher U, Stuetzer H, Roth B. Remifentanil-induced tolerance, withdrawal or hyperalgesia in infants: a randomized controlled trial. RAPIP trial: remifentanil-based analgesia and sedation of paediatric intensive care patients. Neonatology 2013; 104(1):34–41.

70. Wille S, Al Mahmid M, Schumacher P, Poyi-Kamdem M, Tok A, Muthen N, Özgür E, Engelmann UH. Urodynamic effect of 80 watt photoselective laser vaporization of the prostate. Scand J Urol 2013; 47(5):378–83.

71. Würthwein G, Cornely OA, Trame MN, Vehreschild JJ, Vehreschild MJGT, Farowski F, Müller C, Boos J, Hempel G, Hallek M, Groll AH. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob. Agents Chemother. 2013; 57(4):1664–71.

72. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. 2012; 18 Suppl 7:19–37.

73. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. The Lancet Infectious Diseases 2012; 12(4):281–9.

74. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, Jensen HE, Lass-Flörl C, Richardson MD, Akova M, Bassetti M, Calandra T, Castagnola E, Cornely OA, Garbino J, Groll AH, Herbrecht R, Hope WW, Kullberg BJ, Lortholary O, Meersseman W, Petrikkos G, Roilides E, Viscoli C, Ullmann AJ. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin. Microbiol. Infect. 2012; 18 Suppl 7:9–18.

75. Dreß J. Validierung computergeschützter Systeme im GCP-Umfeld: Eine Einführung. Pharm Ind 2012; (12):1945–9.

76. Georgias C, Grunow A, Olderog M, May A, Paulus U. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model. Clinical Trials 2012:781–7.

77. Hamacher J, Tenholte D, Schumacher P, Muthen N, Mehner J, Engelmann U, Wille S. A new catheterless urodynamics measurement method by using an intravesical capsule. Biomedical Engineering / Biomedizinische Technik 2012; 57(SI-1 Track-L).

78. Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Cornely OA, Cuenca-Estrella M, Donnelly JP, Garbino J, Herbrecht R, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Verweij PE, Viscoli C, Ullmann AJ. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin. Microbiol. Infect. 2012; 18 Suppl 7:38–52.

79. Lortholary O, Petrikkos G, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Cuenca-Estrella M, Donnelly JP, Garbino J, Groll AH, Herbrecht R, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Meersseman W, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin. Microbiol. Infect. 2012; 18 Suppl 7:68–77.

80. Michalik C, Königs C, Gingelmaier A, Skaletz-Rorowksi A, Brockmeyer NH. Frauen mit HIV in Deutschland: Schwangerschaft und Kinder. Daten aus der Schwangeren- und Kinder-Kohorte des Kompetenznetzes HIV/AIDS. ♀x-Change: aktuelle Informationen zu HIV & Frauen 2012.

81. Ruhnke M, Böhme A, Buchheidt D, Cornely O, Donhuijsen K, Einsele H, Enzensberger R, Hebart H, Heussel CP, Horger M, Hof H, Karthaus M, Krüger W, Maschmeyer G, Penack O, Ritter J, Schwartz S. Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann. Oncol. 2012; 23(4):823–33.

82. Skaletz-Rorowksi A, Michalik C, Brockmeyer NH. Biomaterialbanken im Kompetenznetz HIV/AIDS: Konzepte und Potenziale für eine individualisierte Medizin. Med Welt 2012; (3):1–4.

83. Stahl A, Krohne TU, Limburg E. Register zur Erfassung behandlungsbedürftiger Frühgeborenenretinopathie. Zeitschrift für praktische Augenheilkunde 2012; (33):500–4.

84. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin. Microbiol. Infect. 2012; 18 Suppl 7:53–67.

85. Ullmann AJ, Cornely OA, Donnelly JP, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Garbino J, Groll AH, Herbrecht R, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Cuenca-Estrella M. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin. Microbiol. Infect. 2012; 18 Suppl 7:1–8.

86. Vehreschild JJ, Moritz G, Vehreschild MJGT, Arenz D, Mahne M, Bredenfeld H, Chemnitz J, Klein F, Cremer B, Böll B, Kaul I, Wassmer G, Hallek M, Scheid C, Cornely OA. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. Int. J. Antimicrob. Agents 2012; 39(2):130–4.

87. Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G, Heinz W, Karthaus M, Kiehl M, Krüger W, Penack O, Reuter S, Ruhnke M, Sandherr M, Salwender H, Ullmann AJ, Waldschmidt DT, Wolf HH. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol. 2012; 91(8):1161–74.

88. Welzing L, Oberthuer A, Junghaenel S, Harnischmacher U, Stützer H, Roth B. Remifentanil/midazolam versus fentanyl/midazolam for analgesia and sedation of mechanically ventilated neonates and young infants: a randomized controlled trial. Intensive Care Med 2012; 38(6):1017–24.

89. Borchmann P, Haverkamp H, Fuchs M, Eich H, Mueller-Hermelink HK, Cerny T, Markova J, D. Ho A, Kanz L, Greil R, Hiddemann W, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause S, Mueller R, Diehl V, Engert A. Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG). Journal of Clinical Oncology 2011.

90. Cornely OA, Vehreschild JJ, Vehreschild MJGT, Würthwein G, Arenz D, Schwartz S, Heussel CP, Silling G, Mahne M, Franklin J, Harnischmacher U, Wilkens A, Farowski F, Karthaus M, Lehrnbecher T, Ullmann AJ, Hallek M, Groll AH. Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis. Antimicrob. Agents Chemother. 2011; 55(12):5798–803. Available from: URL:doi:10.1128/AAC.05134-11.

91. Dreß J, Harnischmacher U, Weiß C, Leyendecker I, Niewerth U, Paulus U. High quality risk management for clinical trials: use the data at your hands to manage risk in your clinical trials. In: 32nd Annual Meeting; 2011. p. 68 .

92. Grunow A, Georgias C, Paulus U. Academic Trials and the challenge of sponsor responsibility. In: 32nd Annual Meeting; 2011. p. 54–5 .

93. Lehmacher W, Wolff S. Die Bedeutung von Head-to-Head-Studien für die versorgungsnahe klinische Forschung: The relevance of head-to-head trials to patient-centred clinical research. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2011; 105(9):639–45. Available from: URL:doi:10.1016/j.zefq.2011.10.028.

94. Mönkemann H, Olderog M, Paulus U. Harmonized standrad operating procedures for academic trials. In: 32nd Annual Meeting; 2011. p. 55 .

95. Mueller SM, Spriewald BM, Bergmann S, Eismann K, Leykauf M, Korn K, Walter H, Schmidt B, Arnold M, Harrer EG, Kaiser R, Schweitzer F, Braun P, Reuter S, Jaeger H, Wolf E, Brockmeyer NH, Jansen K, Michalik C, Harrer T. Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognition. J. Acquir. Immune Defic. Syndr. 2011; 56(2):109–17. Available from: URL:doi:10.1097/QAI.0b013e3181fe946e.

96. Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, Rausch M, Hower M, Ulmer A, Wolf E, Lorenzen T, Arendt G, Jansen K. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. Infection 2011; 39(1):3–12. Available from: URL:doi:10.1007/s15010-010-0070-8.

97. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH, Mallmann P, Stepan H, Karumanchi SA, Benzing T. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124(8):940–50. Available from: URL:doi:10.1161/CIRCULATIONAHA.111.034793.

98. Vehreschild MJGT, Meissner A, Cornely OA, Maschmeyer G, Neumann S, Lilienfeld-Toal M von, Karthaus M, Wattad M, Staib P, Hellmich M, Christ H, Vehreschild J. A clinical definition for chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. Haematologica 2011. Available from: URL:doi:10.3324/haematol.2011.049627.

99. Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. The Journal of antimicrobial chemotherapy 2011; 66(9):2092–8. Available from: URL:doi:10.1093/jac/dkr272.

100. Dreß J, Antony G, Grün M, Kotsch J, Krockenberger K, Stausberg J, Thiemann V, Verplancke P. Handlungsspielräume für die klinische Forschung mit IT Service Management eröffnen. In: 55. GMDS Jahrestagung 2010: Effiziente und wirtschaftliche Gesundheitsversorgung von heute und morgen - nur mit Medizinischer Dokumentation, Medizinischer Informatik, Medizinischer Biometrie und Epidemiologie; 55. GMDS Jahrestagung Mannheim 05.09-09.09.2010. Dietzenbach: Antares Computer Verlag GmbH; 2010 (vol. 55).